about
Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic SyndromePoint: Chronic Activation of the Sympathetic Nervous System is the Dominant Contributor to Systemic HypertensionHome blood pressure monitoring: Australian Expert Consensus Statement.Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial.Recurrent postural vasovagal syncope: sympathetic nervous system phenotypes.Guideline for the diagnosis and management of hypertension in adults - 2016.The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice.The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension.Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease.Renal oxygenation in acute renal ischemia-reperfusion injury.Device-based approaches for renal nerve ablation for hypertension and beyond.Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY StudyRenal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney.Renal denervation in hypertensive patients not on blood pressure lowering drugs.European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions.Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation.ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice.Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.The role of sympathetic nervous activity in renal injury and end-stage renal disease.Neck Circumference Is Associated with Muscle Sympathetic Nerve Activity in Overweight and Obese Men but Not Women.New drugs, procedures, and devices for hypertension.Effects of renal denervation on insulin resistance.Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.The role of renal denervation for the treatment of resistant hypertension.Renal sympathetic nerve ablation for the management of resistant hypertension: an update.Regulation of the sympathetic nervous system by the kidney.Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation.Reinnervation following catheter-based radio-frequency renal denervation.First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.The Role of Central Nervous System Mechanisms in Resistant Hypertension.New developments in the pathogenesis of obesity-induced hypertension.Is it time to think about the sodium glucose co-transporter 2 sympathetically?The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease.Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?Device Therapies for Resistant Hypertension.Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension.Serum uric acid and the relationship with subclinical organ damage in adults.
P50
Q21284498-4DA1B63A-B355-471F-AC37-D2BBF3FC3A2CQ22306470-B5F6DD68-AFF2-4C99-8257-913B877FFDCEQ27024621-4BBA97AE-E0EE-4E60-9FFA-8A11D005C79EQ30772422-B366D8EE-11C5-4AFD-A30E-8FE6D73AD8BEQ33160354-330FC564-7EEA-4414-8390-5254C71F1369Q33167507-A3CF2780-5D48-410F-A67D-E5408ACCF3CFQ33624987-2978B5F6-E6D8-450B-9639-EEA44FB7F767Q33736684-BFCCF50B-40E3-4FF7-AAF1-0A1811CE1C19Q34491451-3FB89101-6BD2-481E-97B8-CBD0EE9A70CFQ35112037-FCFB1909-3B93-4851-A050-3D296F268758Q35830968-EE73E8BB-4E26-484D-899B-77548035048EQ35935011-CBEF6225-CE2B-433E-A2F5-452174D0873DQ36682635-8E014212-0867-44E7-BEAC-8175D5CDEB78Q36937415-E0DC164A-9F37-48C3-A3B4-284F7F85399BQ37184474-6BD12F09-D6D5-4B57-B1FF-6B07A239B52FQ37373256-EACD82FF-0065-4238-BB17-CC43E978F2A1Q37639873-5746E5A6-D863-4794-9F3D-96AFDEA67A0DQ37654401-2F9D226F-828E-41AC-99BB-43C0676E568CQ37695713-E979B75E-0DC7-42FE-A359-0C0F095906ABQ37719241-6FF0E69E-162E-41C7-B796-6FA4A7BE92D5Q37739108-E50692CF-B3F2-4B46-A024-60B54DC04709Q38033767-8A8476FA-EC62-4216-857C-675AE15262BBQ38067774-866C74C6-46BD-4404-9349-945E61634EEAQ38111572-6348D4AC-C3C8-44F7-9374-47656BCA7598Q38135985-875A2018-90F8-4B2B-9A09-A0F55B316047Q38148656-B1FB9F99-0A20-400E-9F67-B7B275BCF058Q38150047-84B01850-E1C3-473E-8AD7-5DD8AD9108DFQ38166175-E0095F2F-05B4-4E3F-9B32-46FB45EBC1ECQ38170085-7758C184-3622-44D6-AF54-609C4CA20B44Q38312268-E09AAB1A-6225-4016-9881-C7C896B5B48EQ38416108-2550705E-70F3-42F6-B75E-65EE246AD188Q38526496-C3554883-11E5-4C7A-BDCF-07C58B948005Q38535447-CA20E091-939A-43A1-94C6-F2A6B3AABFE8Q38586588-F2C3F98A-90CE-4712-94F3-DD3716549E19Q38689037-823A6EF2-52E1-4717-ACBE-FAAEC15E2EE3Q38701602-F2187572-2E81-42A6-AE6B-BCB655C90667Q38817369-C008A2D4-A975-427D-B9EC-B1BFDE261146Q38871976-C0174449-B470-4335-A692-0D9CA1E8D82FQ38879588-7AA54AA1-722F-4409-AC16-7B18AC095E10Q38935643-D013CA62-A71E-47B3-BD50-ED51F92422C3
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Markus P Schlaich
@nl
Markus P Schlaich
@sl
Markus P. Schlaich
@en
Markus P. Schlaich
@es
Markus Schlaich
@fr
type
label
Markus P Schlaich
@nl
Markus P Schlaich
@sl
Markus P. Schlaich
@en
Markus P. Schlaich
@es
Markus Schlaich
@fr
prefLabel
Markus P Schlaich
@nl
Markus P Schlaich
@sl
Markus P. Schlaich
@en
Markus P. Schlaich
@es
Markus Schlaich
@fr
P214
P244
P106
P1153
7003349164
P21
P214
P244
nb2015000636
P31
P496
0000-0002-1765-0195
P735
P7859
lccn-nb2015000636